Organization · Venture Capital
Pacific Bridge NY
Pacific Bridge NY is a cross-border venture capital fund based in New York, specializing in biotech investments that leverage connections between Asia and Western markets. The firm focuses on developing scientifically robust biotech assets through US-centric clinical strategies.
Overview
What Pacific Bridge NY does
What Pacific Bridge NY is
Pacific Bridge NY is a cross-border venture capital fund based in New York, specializing in biotech investments that leverage connections between Asia and Western markets. The firm focuses on developing scientifically robust biotech assets through US-centric clinical strategies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- April 23, 2026
Official channels
Find Pacific Bridge NY elsewhere
Open the official website or a supported primary organization account.
Capability profile
Pacific Bridge NY as a funder
Investment thesis
Pacific Bridge NY focuses on unlocking cross-border biotech value, particularly between Asia and the West, by advancing high-quality global intellectual property through cost-effective clinical development strategies.
Focus narrative
PBNY invests in biotech companies and programs that exhibit strong biological rationale and clear paths to approval in Western markets. The fund emphasizes cross-border opportunity sourcing, clinical expertise, and flexible company-building structures, supporting opportunities where global intellectual property can be licensed or partnered.
Value beyond capital
Pacific Bridge NY adds value by providing clinical expertise and facilitating the development of biotech assets through US-centric clinical programs, enabling successful navigation of approval pathways in Western markets.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- North AmericaAsia
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 1
Portfolio context
Notable portfolio company includes Formation Bio, which acquired worldwide rights to LNK01006, a next-gen CNS-penetrant highly selective TYK2 inhibitor from Lynk Pharmaceuticals.
Common questions
What to know about Pacific Bridge NY
Upseed classifies Pacific Bridge NY under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 23, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.